Table 1.
Clinicopathological characteristics with ATP7B protein expression in 158 NSCLC patients treated with platinum-based chemotherapy.
| Characteristics | All patients | ATP7B (+) n (%) |
ATP7B (-) n (%) |
p value |
|---|---|---|---|---|
| All patients | 158 (100.0) | 98 (62.0) | 60 (38.0) | |
| Age | ||||
| <60 years | 80 (50.6) | 51 (52.0) | 29 (48.3) | 0.651 |
| ≥60years | 78 (49.4) | 47 (48.0) | 31 (51.7) | |
| Gender | ||||
| Male | 135 (85.4) | 80 (81.6) | 55 (91.7) | 0.083 |
| Female | 23 (14.6) | 18 (18.4) | 5 (8.3) | |
| Histology | ||||
| Adenocarcinoma | 60 (38.0) | 43 (43.9) | 17 (28.3) | 0.138 |
| Squamous cell carcinoma | 95 (60.0) | 53 (54.1) | 42 (70.0) | |
| Adenosquamous | 3 (2.0) | 2 (2.0) | 1 (1.7) | |
| Clinical stage | ||||
| II | 6 (3.8) | 2 (2.0) | 4 (6.7) | 0.334 |
| III | 56 (35.4) | 35 (35.7) | 21 (35.0) | |
| IV | 96 (60.8) | 61 (62.3) | 35 (58.34) | |
| Differentiation | ||||
| Poor | 67 (42.4) | 43 (43.9) | 24 (40.0) | 0.695 |
| Moderate | 74 (46.8) | 46 (46.9) | 28 (46.7) | |
| Well | 17 (10.8) | 9 (9.2) | 8 (13.3) | |
| Chemotherapy response | ||||
| Responders | 64 (40.5) | 33 (33.7) | 31 (51.7) | 0.025 |
| Nonresponders | 94 (59.5) | 65 (66.3) | 29 (48.3) |